These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: CMV: the other virus.
    Author: Smart T.
    Journal: GMHC Treat Issues; 1996 Mar; 10(3):10-1. PubMed ID: 11363389.
    Abstract:
    The Food and Drug Administration (FDA) approved the use of Gilead Sciences' intravenous drug, cidofovir, for people with CMV retinitis. The FDA also granted final marketing approval for ganciclovir eye implants sold by Chiron Vision. Chiron and Hoffmann-La Roche are co-marketing the device. The device costs $4,000, plus the cost of surgically fastening the device to the eye, which can be as much as $6,000. The device needs to be replaced every six months. The FDA advisory panel also recommended approving cidofovir as systemic treatment for new or relapsing CMV retinitis in people with AIDS. The drug is currently available free in an expanded access program or as a follow-up to trials. Participants must have experienced CMV relapse on either ganciclovir or foscarnet. Many fear that levels of the drug reaching the eye from oral doses are suboptimal and may induce drug resistance, although observations suggest that resistance is a rare occurrence.
    [Abstract] [Full Text] [Related] [New Search]